The Royal Australian and New Zealand College of Obstetricians and Gynaecologists supports the "cautious" decision of the medical watchdog to ban the use of vaginal mesh implants for pelvic prolapse.
However, it has called for good quality research to guide its appropriate use.
Dozens of women have complained of chronic pain or being unable to have sex after an implant, and the use of vaginal mesh has been the subject of a Senate inquiry on its use in Australia.
Based on a review of the evidence, the Therapeutic Goods Administration (TGA) this week announced it will remove transvaginal mesh products used solely to treat pelvic organ prolapse from the Australian Register of Therapeutic Goods (ARTG).
Similarly, single incision mini-slings - commonly used to treat urinary incontinence - will also be removed from the ARTG due to a lack of "adequate scientific evidence" to show that the benefits outweigh the risk.
The changes to the registry take effect from February 4.
"It has become clear that the evidence underpinning the safety and usefulness of mesh used for prolapse is of questionable value. RANZCOG takes on board the decision made by the TGA as the regulatory body for Australian implants," RANZCOG President, Professor Steve Robson, said in a statement on Friday.
"Until such time that the evidence of scientific studies provides a more persuasive argument in favour of mesh kits in the treatment of vaginal prolapse, RANZCOG supports this cautious approach."
Mr Robson also noted that the TGA has not removed mid-uretheral slings from the ARTG.
There are numerous types of vaginal mesh and earlier this year the RANZCOG president stated he would not support a blanket ban.
The Consumers Health Forum has renewed calls for the introduction of a mandatory register to record problems with implants, and for the medical profession to take a more active role in alerting the TGA when problems emerge.
